NCT03530683

A study about combination cancer treatments for people with acute myeloid leukemia or multiple myeloma

The TTI-622-01 (C4971001) study is testing an investigational study medicine for people with acute myeloid leukemia or multiple myeloma. The study medicine works by blocking signals in your immune system, allowing it to attack and kill the cancer cells.

Card Summary Component

Who may participate

Joining a clinical trial is an important and personal decision. Thank you for considering the TTI-622-01 (C4971001) study.

This study may be an option for men and women aged 18 and older who have acute myeloid leukemia or multiple myeloma.

If this study may be a fit for you, you’ll review the details with the study team and get to ask any questions you have. If you choose to participate, you will sign an informed consent document and continue to a screening appointment. This is to confirm you meet the eligibility criteria and are able to participate.

Condition

Acute myeloid leukemia or multiple myeloma

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Age

18 years and older

The age a person must be to participate in a clinical trial.

Sex

Male or Female

The sex of people who may participate in a clinical trial. Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

Card Summary Component

What to expect

Study participants can expect to be in the study for up to 42 months. During this time, participants may continue to receive the study treatments until they no longer benefit from them.

The total time in the study depends upon how well a study participant tolerates the study medicine and how their cancer responds to the treatment(s).

Length of study treatment

Up to 42 months

Length of study treatment is the length of time the study participants will receive the study treatment.

Number of study visits

At least weekly

Each clinical trial’s design specifies the number of study visits and the total length of the trial.

Long-Term Follow-up

1 year

Some studies require the study team to stay in contact with the participant for a period of time after the participant completes the main part of the study. This long-term follow up is to collect additional information on the study drug over time.

Frequently asked questions

What is Acute Myeloid Leukemia?

Acute myeloid leukemia (AML) is a blood cancer that starts in the bone marrow and spreads to the blood. In AML, the body overproduces immature blood cells that, unable to function properly, end up crowding out healthy blood cells.

Is this page helpful?
0
0

What is Multiple Myeloma?

Multiple myeloma is a type of blood cancer that forms in bone marrow. Healthy bone marrow produces plasma cells, which make antibodies to fight infection. But in multiple myeloma, plasma cells become cancerous. These cancer cells can crowd out normal blood cells, forming tumors and leaving a person vulnerable to infection.

Is this page helpful?
0
0

How does the study medicine work?

The study medicine works by helping your immune system to target and kill cancer cells.

Is this page helpful?
0
0